FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901684370> ?p ?o ?g. }

• W2901684370 abstract "A head-to-head study demonstrated the superiority of once-daily umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg on trough forced expiratory volume in 1 s (FEV1) versus once-daily tiotropium/olodaterol (TIO/OLO) 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease (COPD). This analysis evaluated the cost effectiveness of UMEC/VI versus TIO/OLO from a Spanish National Healthcare System perspective, using data from this study and Spanish literature. This analysis was conducted from the perspective of the Spanish National Healthcare System with a 3-year horizon as base case. A disease progression model using a linked risk equation approach was used to estimate disease progression and associated healthcare costs, and quality-adjusted life years (QALYs). The Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study was used to develop the statistical risk equations for clinical endpoints, and costs were calculated using a health state approach (by dyspnea severity). Utilities for QALY calculation were estimated using patient baseline characteristics within a regression fit to Spanish observational data. Treatment effect, expressed as change from baseline in FEV1 was obtained from the head-to-head study and used in the model (UMEC/VI minus TIO/OLO difference: + 52 mL [95% confidence interval: 28, 77]). Baseline patient characteristics were sourced from Spanish literature or the head-to-head study if unavailable. A scenario analysis using only the intent-to-treat (ITT) population from the head-to-head study, and sensitivity analyses (including probabilistic sensitivity analyses), were conducted. Direct healthcare costs (2017 Euro) were obtained from Spanish sources and costs and benefits were discounted at 3% per annum. UMEC/VI was associated with small improvements in QALYs (+ 0.029) over a 3-year time horizon, compared with TIO/OLO, alongside cost savings of €393/patient. The ITT scenario analysis and sensitivity analyses had similar results. All probabilistic simulations resulted in UMEC/VI being less costly and more effective than TIO/OLO. UMEC/VI dominated TIO/OLO (more effective and less expensive). These results may aid payers and decision-makers in Spain when making judgements on which long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) treatments can be considered cost effective in Spain." @default.
• W2901684370 created "2018-11-29" @default.
• W2901684370 creator A5025233034 @default.
• W2901684370 creator A5029294647 @default.
• W2901684370 creator A5038171945 @default.
• W2901684370 creator A5039975367 @default.
• W2901684370 creator A5048130857 @default.
• W2901684370 creator A5053324168 @default.
• W2901684370 creator A5058947386 @default.
• W2901684370 creator A5071831143 @default.
• W2901684370 creator A5078491071 @default.
• W2901684370 creator A5087152114 @default.
• W2901684370 date "2018-11-20" @default.
• W2901684370 modified "2023-10-18" @default.
• W2901684370 title "Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective" @default.
• W2901684370 cites W1481550704 @default.
• W2901684370 cites W1553966959 @default.
• W2901684370 cites W1631769030 @default.
• W2901684370 cites W1977628820 @default.
• W2901684370 cites W2004200914 @default.
• W2901684370 cites W2022512296 @default.
• W2901684370 cites W2023136584 @default.
• W2901684370 cites W2026033029 @default.
• W2901684370 cites W2026585673 @default.
• W2901684370 cites W2039237831 @default.
• W2901684370 cites W2056267346 @default.
• W2901684370 cites W2102590607 @default.
• W2901684370 cites W2105234929 @default.
• W2901684370 cites W2106232279 @default.
• W2901684370 cites W2108123132 @default.
• W2901684370 cites W2122286642 @default.
• W2901684370 cites W2127951128 @default.
• W2901684370 cites W2130138851 @default.
• W2901684370 cites W2137457973 @default.
• W2901684370 cites W2141034778 @default.
• W2901684370 cites W2142096203 @default.
• W2901684370 cites W2144776919 @default.
• W2901684370 cites W2163317499 @default.
• W2901684370 cites W2165196908 @default.
• W2901684370 cites W2166432084 @default.
• W2901684370 cites W2167795093 @default.
• W2901684370 cites W2229336932 @default.
• W2901684370 cites W2287635305 @default.
• W2901684370 cites W2299097941 @default.
• W2901684370 cites W2306167922 @default.
• W2901684370 cites W2313271471 @default.
• W2901684370 cites W2334564051 @default.
• W2901684370 cites W2345348650 @default.
• W2901684370 cites W2346277111 @default.
• W2901684370 cites W2444230658 @default.
• W2901684370 cites W2468367644 @default.
• W2901684370 cites W2493396323 @default.
• W2901684370 cites W2552991232 @default.
• W2901684370 cites W2558950195 @default.
• W2901684370 cites W2568629548 @default.
• W2901684370 cites W2580211495 @default.
• W2901684370 cites W2587433062 @default.
• W2901684370 cites W2593670800 @default.
• W2901684370 cites W2601087692 @default.
• W2901684370 cites W2605835591 @default.
• W2901684370 cites W2610956233 @default.
• W2901684370 cites W2742973125 @default.
• W2901684370 cites W2747887656 @default.
• W2901684370 cites W2766657020 @default.
• W2901684370 cites W2767010890 @default.
• W2901684370 cites W2769313882 @default.
• W2901684370 cites W2796654667 @default.
• W2901684370 cites W4211263216 @default.
• W2901684370 cites W4242667311 @default.
• W2901684370 doi "https://doi.org/10.1186/s12931-018-0916-7" @default.
• W2901684370 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6348614" @default.
• W2901684370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30691468" @default.
• W2901684370 hasPublicationYear "2018" @default.
• W2901684370 type Work @default.
• W2901684370 sameAs 2901684370 @default.
• W2901684370 citedByCount "6" @default.
• W2901684370 countsByYear W29016843702019 @default.
• W2901684370 countsByYear W29016843702020 @default.
• W2901684370 countsByYear W29016843702021 @default.
• W2901684370 countsByYear W29016843702022 @default.
• W2901684370 crossrefType "journal-article" @default.
• W2901684370 hasAuthorship W2901684370A5025233034 @default.
• W2901684370 hasAuthorship W2901684370A5029294647 @default.
• W2901684370 hasAuthorship W2901684370A5038171945 @default.
• W2901684370 hasAuthorship W2901684370A5039975367 @default.
• W2901684370 hasAuthorship W2901684370A5048130857 @default.
• W2901684370 hasAuthorship W2901684370A5053324168 @default.
• W2901684370 hasAuthorship W2901684370A5058947386 @default.
• W2901684370 hasAuthorship W2901684370A5071831143 @default.
• W2901684370 hasAuthorship W2901684370A5078491071 @default.
• W2901684370 hasAuthorship W2901684370A5087152114 @default.
• W2901684370 hasBestOaLocation W29016843701 @default.
• W2901684370 hasConcept C126322002 @default.
• W2901684370 hasConcept C1862650 @default.
• W2901684370 hasConcept C194828623 @default.
• W2901684370 hasConcept C2776780178 @default.
• W2901684370 hasConcept C2908647359 @default.
• W2901684370 hasConcept C44249647 @default.
• W2901684370 hasConcept C71924100 @default.
• W2901684370 hasConcept C99454951 @default.

• next